In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background Escitalopram is a dual serotonin reuptake inhibitor (SSRI) approved for the treatment of depression and anxiety disorders. It is the S-enantiomer of citalopram, and is responsible for the serotonin reuptake activity, and thus for its pharmacological effects. Previous studies pointed out that clinically efficacious doses of other SSRIs produce an occupancy of the serotonin reuptake transporter (SERT) of about 80% or more. The novel radioligand [123I]ADAM and single photon emission computer tomography (SPECT) were used to measure midbrain SERT occupancies for different doses of escitalopram and citalopram.Methods Twenty-five healthy subjects received a single dose of escitalopram [5 mg (n=5), 10 mg (n=5), and 20 mg (n=5)] or citalopram [(10 mg (n=5) and 20 mg (n=5)]. Midbrain SERT binding was measured with [(123)I]ADAM and SPECT on two study days, once without study drug and once 6 h after single dose administration of the study drug. The ratio of midbrain-cerebellum/cerebellum was the outcome measure (V3") for specific binding to SERT in midbrain. Subsequently, SERT occupancy levels were calculated using the untreated baseline level for each subject. An Emax model was used to describe the relationship between S-citalopram concentrations and SERT occupancy values. Additionally, four subjects received placebo to determine test-retest variability.Results Single doses of 5, 10, or 20 mg escitalopram led to a mean SERT occupancy of 60+/-6, 64+/-6, and 75+/-5%, respectively. SERT occupancies for subjects treated with single doses of 10 and 20 mg citalopram were 65+/-10 and 70+/-6%, respectively. A statistically significant difference was found between SERT occupancies after application of 10 and 20 mg escitalopram, but not for 10 and 20 mg citalopram. There was no statistically significant difference between the SERT occupancies of either 10 mg citalopram or 10 mg escitalopram, or between 20 mg citalopram and 20 mg escitalopram. Emax was slightly higher after administration of citalopram (84%) than escitalopram (79%). In the test-retest study, a mean SERT "occupancy" of 4% was found after administration of placebo, the intraclass correlation coefficient was 0.92, and the repeatability coefficient was 0.25.Conclusion SPECT and [123I]ADAM were used to investigate SERT occupancies after single doses of escitalopram or citalopram. The test-retest study revealed good reproducibility of SERT quantification. Similar SERT occupancies were found after administration of equal doses (in respect to mg) of escitalopram and citalopram, giving indirect evidence for a fractional blockade of SERT by the inactive R-citalopram.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a total of 16 articles (reporting on 17 unique studies) were included [17–19, 28–40].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [18]
Citations
Cites
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · cited 1×
“Adverse events were assessed by the UKU side effects scale ( Lingjaerde et al. 1987 ).”
MethodMeyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 3×
“Furthermore, they found a significant relationship between SERT occupancy and serum concentration after administration of citalopram ( Meyer et al. 2004 ), which was not observed in the present study.”
BackgroundResultInfluentialReduced Serotonin Type 1AReceptor Binding in Panic Disorder: Figure 1.
Neumeister, A., Bain, E., Nugent, A. C., Carson, R. E., Bonne, O., Luckenbaugh, D. A., Eckelman, W., Herscovitch, P., Charney, D. S., & Drevets, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4921-03.2004 · Cited by 355
Laruelle, M., Baldwin, R. M., Malison, R. T., Zea‐Ponce, Y., Zoghbi, S. S., Al‐Tikeriti, M. S., Sybirska, E. H., Zimmermann, R. C., Wisniewski, G., Neumeyer, J. L., et al. (1993) · Synapse · doi:10.1002/syn.890130402 · Cited by 351
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340
Dysfunctional Attitudes and 5-HT2 Receptors During Depression and Self-Harm
Meyer, J. H., McMain, S., Kennedy, S. H., Korman, L., Brown, G. M., DaSilva, J. N., Wilson, A. A., Blak, T., Eynan-Harvey, R., Goulding, V. S., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.90 · Cited by 264
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Escitalopram versus citalopram: the surprising role of the R-enantiomer
S�nchez, C., B�ges�, K., Ebert, B., Reines, E., & Braestrup, C. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1865-z · Cited by 248
Moore, N., Verdoux, H., & Fantino, B. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200505000-00002 · Cited by 188
Willeit, M., Praschak-Rieder, N., Neumeister, A., Pirker, W., Asenbaum, S., Vitouch, O., Tauscher, J., Hilger, E., Stastny, J., Brücke, T., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00293-0 · Cited by 179
Self-citation
Research works printed but not linked: 4
- Alexopoulos GS, Privitera W, Ventura D, Bose A, Lenz SM, Wang Q (2004) Fixed dose of escitalopram (10 mg/day) and a flexible dosing regime of sertraline (50–200 mg/day) in a randomized, double-blind comparison in depressed patients. World J Biol Psychiatry 5(Suppl 1):97
- Baumann P, Larsen F (1995) The pharmacokinetics of citalopram. Rev Contemp Pharmacother 6:287–295
- Klein N, Sacher J, Mossaheb N, Asenbaum S, Pötzi C, Dobrozemsky G, Dudczak R, Kasper S, Tauscher J (2004) Quantification of serotonin transporters with [123I]ADAM and SPECT in healthy human subjects: preliminary data on tracer kinetics. Biol Psychiatry 55:S212
- Sacher J, Asenbaum S, Klein N, Geiss-Granadia T, Mossaheb N, Pötzi C, Attarbaschi T, Lanzenberger R, Dudczak R, Kasper S, Tauscher J (2006) [123I]ADAM: a novel SPECT ligand for quantification of serotonin transporters in humans. Int J Neuropsychopharmacology (in press)
Cited by
5‐HT radioligands for human brain imaging with PET and SPECT
Paterson, L. M., Kornum, B. R., Nutt, D. J., Pike, V. W., & Knudsen, G. M. (2013) · Medicinal Research Reviews · doi:10.1002/med.20245 · Cited by 151
Herrmann, N., Black, S. E., Chow, T. W., Cappell, J., Tang‐Wai, D. F., & Lanctôt, K. L. (2011) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31823033f3 · Cited by 146
Windischberger, C., Lanzenberger, R., Holik, A., Spindelegger, C., Stein, P., Moser, U., Gerstl, F., Fink, M., Moser, E., & Kasper, S. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.013 · Cited by 114
Self-citationImproving response inhibition systems in frontotemporal dementia with citalopram
Hughes, L. E., Rittman, T., Regenthal, R., Robbins, T. W., & Rowe, J. B. (2015) · Brain · doi:10.1093/brain/awv133 · Cited by 100
“Second, is to identify pharmacological targets for treatment based on the psychopharmacology of re- sponse inhibition and the neurotransmitter deficits in bvFTD.”
BackgroundBonaventure, P., Dugovic, C., Kramer, M. L., Boer, P. D., Singh, J. B., Wilson, S. J., Bertelsen, K. M., Di, J., Shelton, J. E., Aluisio, L. E., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.193995 · Cited by 100
“Investigations of the 5-HT transporter occupancy by using positron emission tomography have demonstrated an average 5-HT transporter occupancy after a single dose of 20 mg of citalopram of 70%, whereas 20 mg of escitalopram led to a 5-HT transporter occupancy of 75% (Klein et al., 2006).”
Metadata
- Authors
- Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., Dudczak, R., Tauscher, J., & Kasper, S.
- Affiliations
- University of Vienna (AT)
- Medical University of Vienna (AT)
- Corresponding author
- Kasper, S.
- Venue
- Psychopharmacology
- Published
- 2006-09-06
- Volume
- 188
- Issue
- 3
- Pages
- 263-272
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2035444856
- Cited by
- 77
- References
- 44
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 1 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 2 · 2012: 3
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- H. Lundbeck A/S
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- escitalopram, citalopram, midbrain, dose-response relationship, Emax model, serotonin reuptake inhibitors, radioligand binding, healthy volunteers, test-retest variability, pharmacodynamic imaging, depression treatment, anxiety disorder treatment
- MeSH terms
- Administration, Oral, Adult, Cerebellum, Cinanserin, Dose-Response Relationship, Drug, Humans, Iodine Radioisotopes, Male, Mesencephalon, Metabolic Clearance Rate, Nausea, Protein Binding, Sleep Wake Disorders, Stereoisomerism, Time Factors, Xerostomia, Citalopram, Tomography, Emission-Computed, Single-Photon, Akathisia, Drug-Induced, Selective Serotonin Reuptake Inhibitors, Area Under Curve, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. https://app.cochat.ai/papers/10.1007/s00213-006-0486-0
- The paper
- Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., Dudczak, R., Tauscher, J., & Kasper, S. (2006). In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology. https://doi.org/10.1007/s00213-006-0486-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.